Benjamin Jackson CFA, an analyst from Jefferies, maintained the Buy rating on Galderma Group AG. The associated price target remains the same with CHF160.00.
TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Benjamin Jackson CFA has given his Buy rating due to a combination of factors that suggest Galderma Group AG is well-positioned to manage potential challenges. Despite the recent announcement of a 100% tariff on pharmaceutical imports by the Trump administration, Galderma’s exposure through its Therapeutic Dermatology and Neuromodulator portfolio is expected to remain manageable. This assumption is based on the belief that the EU’s 15% tariff cap will hold, minimizing the impact on Galderma’s operations.
Moreover, Galderma has potential mitigation strategies in place, which could be crucial given the unpredictable nature of tariff policies. Additionally, the growth of Nemluvio is progressing in line with optimistic forecasts, further supporting the positive outlook for the company. These factors collectively underpin the Buy rating, as they indicate that Galderma is capable of navigating the current economic uncertainties while maintaining its growth trajectory.
According to TipRanks, Jackson CFA is a 3-star analyst with an average return of 4.1% and a 62.50% success rate. Jackson CFA covers the Healthcare sector, focusing on stocks such as Galderma Group AG, Novartis AG, and AstraZeneca.
In another report released on September 22, Kepler Capital also maintained a Buy rating on the stock with a CHF165.00 price target.